GB Sciences (GBLX) 10-Q 14 Aug 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2023	Aug. 14, 2023
Document Information [Line Items]
Entity Central Index Key	0001165320
Entity Registrant Name	GB SCIENCES INC
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	000-55462
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	59-3733133
Entity Address, Address Line One	9205 W. Russell Road, Suite 240
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89148
City Area Code	866
Local Phone Number	721-0297
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		381,872,561

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2023	Mar. 31, 2023
Cash and cash equivalents	$ 29,611	$ 109,912
Prepaid expenses and other current assets	199,592	199,592
TOTAL CURRENT ASSETS	229,203	309,504
Intangible assets, net of accumulated amortization and impairment of $2,433,116 and $2,390,297 at June 30, 2023 and March 31, 2023, respectively	0	42,819
TOTAL ASSETS	229,203	352,323
CURRENT LIABILITIES:
Accrued interest	372,535	346,806
Accrued liabilities	75,628	75,628
Notes and convertible notes payable and line of credit, net of unamortized discount of $26,155 and $41,230 at June 30, 2023 and March 31, 2023, respectively	1,411,152	1,396,077
Income taxes payable	958,455	958,455
TOTAL CURRENT LIABILITIES	4,884,707	4,759,706
Long-term convertible notes payable	25,000	0
TOTAL LIABILITIES	4,909,707	4,759,706
Commitments and contingencies (Note 5)
STOCKHOLDERS' DEFICIT:
Common Stock, $0.0001 par value, 950,000,000 shares authorized, 381,872,561 and 381,872,561 outstanding at June 30, 2023 and March 31, 2023, respectively	38,187	38,187
Additional paid-in capital	104,259,745	104,259,745
Accumulated deficit	108,978,436	108,705,315
TOTAL STOCKHOLDERS' DEFICIT	(4,680,504)	(4,407,383)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	229,203	352,323
Nonrelated Party [Member]
CURRENT LIABILITIES:
Accounts payable	1,946,026	1,861,829
Related Party [Member]
CURRENT LIABILITIES:
Accounts payable	$ 120,911	$ 120,911

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2023	Mar. 31, 2023
Intangible assets, accumulated amortization	$ 2,433,116	$ 2,390,297
Unamortized discount, current	$ 26,155	$ 41,230
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	950,000,000	950,000,000
Common stock, shares issued (in shares)	381,872,561	381,872,561
Common stock, shares outstanding (in shares)	381,872,561	381,872,561

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Sales revenue	$ 0	$ 0
Cost of goods sold	0	0
Gross profit	0	0
General and administrative expenses	265,122	459,517
LOSS FROM OPERATIONS	(265,122)	(459,517)
OTHER INCOME (EXPENSE)
Interest expense	(40,804)	(38,572)
Loss on impairment of capitalized patent and trademark costs	(42,195)	0
Other income	75,000	0
Total other expense	(7,999)	(38,572)
LOSS BEFORE INCOME TAXES	(273,121)	(498,089)
Income tax expense	0	0
NET LOSS	$ (273,121)	$ (498,089)
Net loss per common share – basic and diluted
Weighted average common shares outstanding – basic and diluted (in shares)	381,872,561	325,743,436

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
OPERATING ACTIVITIES:
Net loss	$ (273,121)	$ (498,089)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	624	20,086
Stock-based compensation	0	6,500
Amortization of debt discount and beneficial conversion feature	15,075	15,976
Loss on impairment of capitalized patent and trademark costs	42,195	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	0	37,520
Accounts payable	84,197	66,334
Accrued liabilities	0	39,145
Accrued interest	25,729	20,485
Net cash used in operating activities	(105,301)	(292,043)
FINANCING ACTIVITIES:
Gross proceeds from convertible notes payable	25,000	0
Gross proceeds from issuing common stock	0	125,000
Principal payment on notes and convertible notes payable	0	(12,890)
Net cash provided by financing activities	25,000	112,110
Net change in cash and cash equivalents	(80,301)	(179,933)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	109,912	233,893
CASH AND CASH EQUIVALENTS AT END OF PERIOD	29,611	53,960
Cash paid for interest	0	2,111
Cash paid for income tax	0	0
Non-cash investing and financing transactions:
Patent drafting and filing costs capitalized in intangible assets	0	28,234
Accrued brokerage fees for common stock issuances and warrant exercises	$ 0	$ 16,250

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2022	325,037,557
Balance at Mar. 31, 2022	$ 32,504	$ 102,764,746	$ (104,580,122)	$ (1,782,872)
Stock issued for cash, net of offering costs (in shares)	4,168,334
Stock issued for cash, net of offering costs	$ 417	108,333	0	108,750
Share based compensation expense		6,500		6,500
Net income (loss)	$ 0	0	(498,089)	(498,089)
Balance (in shares) at Jun. 30, 2022	329,205,891
Balance at Jun. 30, 2022	$ 32,921	102,879,579	(105,078,211)	(2,165,711)
Balance (in shares) at Mar. 31, 2023	381,872,561
Balance at Mar. 31, 2023	$ 38,187	104,259,745	(108,705,315)	(4,407,383)
Net income (loss)	$ 0	0	(273,121)	(273,121)
Balance (in shares) at Jun. 30, 2023	381,872,561
Balance at Jun. 30, 2023	$ 38,187	$ 104,259,745	$ (108,978,436)	$ (4,680,504)

Note 1 - Background and Signifi

Note 1 - Background and Significant Accounting Policies	3 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 1 Background and Significant Accounting Policies GB Sciences, Inc. (“the Company”, “GB Sciences”, “GBLX”, “we”, “us”, or “our”) is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned Canadian subsidiary, GbS Global Biopharma, Inc. (“GBSGB”). Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary plant-inspired formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. The Company’s intellectual property portfolio, which is held by GBSGB, contains six eight one three 55 On February 3, 2023, first $8.8 2026, first Several more of GBLX/GBSGB’s foreign patents for plant-based treatments of serious disorders were allowed in different countries, expanding our patent protections as follows. On December 1, 2022, December 15, 2022, February 20, 2023, March 9, 2023, No. 16/878,295. April 25, 2023, GBSGB’s intellectual property covers a range of over 65 five first Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2024. March 31, 2023 not 10 March 31, 2023. Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. All subsidiaries were wholly owned by the Company for the periods presented. GB SCIENCES, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 (unaudited) Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Indefinite and Definite-Lived Intangible Assets Capitalized costs related to our indefinite-lived intangible assets consisted primarily of the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also historically included the acquisition cost of a cannabis production license with an indefinite life. We historically amortized our finite-lived intangible assets, which consisted of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. As of March 31, 2023, March 31, 2023 350 30 35. At June 30, 2023, six two four January 2038 May 2039. three June 30, 2023 2022, There were 10 United States patent applications that are pending as of June 30, 2023, June 30, 2023. June 30, 2023. Included in Intangible assets at June 30, 2023, three June 30, 2023. GB SCIENCES, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 (unaudited) Equity-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 718 505 50 505 50 no may may may Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source was part of discontinued operations prior to the sale of the Nevada Subsidiaries (Note 7 606, may may one 606 not Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company previously operated in the State-licensed cannabis industry through its now-deconsolidated Nevada Subsidiaries, gross profits from those subsidiaries has is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. GB SCIENCES, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 (unaudited) Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 162,611,301 and 123,013,087 potentially dilutive common shares, related to convertible debt, warrants, and stock options, at June 30, 2023 June 30, 2022, not three June 30, 2023 2022, Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 April 1, 2023, not In June 2020, No. 2020 06, may April 1, 2023. 2020 06 April 1, 2023, not All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 Going Concern The Company’s unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $108,978,436 at June 30, 2023. June 30, 2023, March 31, 2023. three June 30, 2023, three June 30, 2022. Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying condensed consolidated financial statements do not may GB SCIENCES, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 (unaudited)

Note 3 - Convertible Notes

Note 3 - Convertible Notes	3 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Convertible Debt [Text Block]	Note 3 Notes and Convertible Notes Payable and Line of Credit At June 30, 2023, three June 30, 2023, As of June 30, 2023 March 31, 2023 As of June 30, 2023 Face Value Discount Carrying Value 6% Convertible promissory notes payable $ 560,000 $ - $ 560,000 6% Convertible notes payable due January 18, 2022 325,000 - 325,000 6% Convertible note payable due July 1, 2022 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 (4,859 ) 192,141 6% Convertible note payable due December 31, 2023 250,000 (21,296 ) 228,704 0% Note Payable dated October 23, 2017 (as amended) 55,307 - 55,307 Total short-term notes and convertible notes payable $ 1,437,307 $ (26,155 ) $ 1,411,152 6% Convertible note payable due June 30, 2026 25,000 - 25,000 Total long-term convertible notes payable 25,000 - 25,000 Total notes and convertible notes payable $ 1,462,307 $ (26,155 ) $ 1,436,152 As of March 31, 2023 Face Value Discount Carrying Value 6% Convertible promissory notes payable $ 560,000 $ - $ 560,000 6% Convertible notes payable due January 18, 2022 325,000 - 325,000 6% Convertible note payable due July 1, 2022 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 (9,475 ) 187,525 6% Convertible note payable due December 31, 2023 250,000 (31,755 ) 218,245 0% Note Payable dated October 23, 2017 (as amended) 55,307 - 55,307 Total short-term notes and convertible notes payable $ 1,437,307 $ (41,230 ) $ 1,396,077 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. On August 10, 2020, December 31, 2021 December 14, 2021. On March 4, 2022, March 4, 2022. GB SCIENCES, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 (unaudited) We evaluated the modification under the guidance in ASC 470 50 10% March 31, 2022, At June 30, 2023, no three June 30, 2023. 8% July 24, 2020 On July 24, 2020, "July 24 may 8% February 28, 2019. July 24 3 July 24 On December 29, 2020, three $325,000 July 24 July 24 one No November 30, 2020. not July 24 March 31, 2021. December 31, 2021, $325,000 March 31, 2021, December 31, 2021, no March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three GB SCIENCES, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 (unaudited) All notes from the March July 2017 March 31, 2022, $197,000 three September 30, 2023. 10% three June 30, 2023, $197,000 June 30, 2023. Three convertible notes totaling $1,060,000 were held by the same investor and in default. On January 20, 2022, one not three June 30, 2023, no June 30, 2023. December 2020 $625,000 6% On December 18, 2020, 19 three January 31, 2021 July 1, 2022, December 2023. March 31, 2022, During the three June 30, 2023, June 29, 2026, no December 2020 $625,000 6% June 30, 2023.

Note 4 - Capital Transactions

Note 4 - Capital Transactions	3 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Equity [Text Block]	Note 4 Capital Transactions Three Months Ended June 30, 2023 Warrants During the three June 30, 2023, no three June 30, 2023, Employee Option Grants During the three June 30, 2023, no three June 30, 2023, GB SCIENCES, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 (unaudited) Year Ended March 31, 2023 Sale of Common Stock and Warrants On May 9, 2022 one one one five September 9, 2022, November 30, 2022 March 31, 2023, $1,483,350 one five As the result of the units sold to date under the private placement, the Company will issue its brokers 5,416,834 compensation warrants to purchase one share of the Company's common stock at $0.03 per share for a period of five Employee Option Grant On August 25, 2022, seven one one

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	3 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 5 Commitments and Contingencies On April 11, 2022, May 2020. may From time to time, the Company may not

Note 6 - Related Party Transact

Note 6 - Related Party Transactions	3 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 6 Related Party Transactions As of June 30, 2023, As of June 30, 2023,

Note 7 - Sale of Membership Int

Note 7 - Sale of Membership Interests in Nevada Subsidiaries	3 Months Ended
	Jun. 30, 2023
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 7 Sale of Membership Interests in Nevada Subsidiaries On March 24, 2020, GB SCIENCES, INC. AND SUBSIDIARIES CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 (unaudited) On August 10, 2020, 483 October 23, 2017 ( 3 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. Note Receivable from Sale of Teco Subsidiaries The $3,025,000 note receivable from the sale of the Teco Subsidiaries is payable as quarterly, interest only payments of $60,500 for the first March 31, 2023, December 31, 2024. The note contains a provision that allows payments of principal and interest due prior to the maturity date to be postponed to the next quarterly payment date if cash flow from the operations of the facility is insufficient to cover the amount of the payment. Several days prior to the first April 1, 2022, April 1, 2022 July 1, 2022 March 31, 2022, During the three June 30, 2023,

Note 8 - Subsequent Events

Note 8 - Subsequent Events	3 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8 Subsequent Events Subsequent to June 30, 2023, June July 2026. Subsequent to June 30, 2023 not GB SCIENCES, INC. AND SUBSIDIARIES Management s Discussion and Analysis of Financial Condition and Results of Operations June 30, 2023 (unaudited)

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2024. March 31, 2023 not 10 March 31, 2023.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. All subsidiaries were wholly owned by the Company for the periods presented.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Indefinite and Definite-Lived Intangible Assets Capitalized costs related to our indefinite-lived intangible assets consisted primarily of the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also historically included the acquisition cost of a cannabis production license with an indefinite life. We historically amortized our finite-lived intangible assets, which consisted of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. As of March 31, 2023, March 31, 2023 350 30 35. At June 30, 2023, six two four January 2038 May 2039. three June 30, 2023 2022, There were 10 United States patent applications that are pending as of June 30, 2023, June 30, 2023. June 30, 2023. Included in Intangible assets at June 30, 2023, three June 30, 2023.
Share-Based Payment Arrangement [Policy Text Block]	Equity-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 718 505 50 505 50 no may may may
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source was part of discontinued operations prior to the sale of the Nevada Subsidiaries (Note 7 606, may may one 606 not
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company previously operated in the State-licensed cannabis industry through its now-deconsolidated Nevada Subsidiaries, gross profits from those subsidiaries has is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 162,611,301 and 123,013,087 potentially dilutive common shares, related to convertible debt, warrants, and stock options, at June 30, 2023 June 30, 2022, not three June 30, 2023 2022,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 April 1, 2023, not In June 2020, No. 2020 06, may April 1, 2023. 2020 06 April 1, 2023, not All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 3 - Convertible Notes (Tab

Note 3 - Convertible Notes (Tables)	3 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Debt [Table Text Block]	As of June 30, 2023 Face Value Discount Carrying Value 6% Convertible promissory notes payable $ 560,000 $ - $ 560,000 6% Convertible notes payable due January 18, 2022 325,000 - 325,000 6% Convertible note payable due July 1, 2022 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 (4,859 ) 192,141 6% Convertible note payable due December 31, 2023 250,000 (21,296 ) 228,704 0% Note Payable dated October 23, 2017 (as amended) 55,307 - 55,307 Total short-term notes and convertible notes payable $ 1,437,307 $ (26,155 ) $ 1,411,152 6% Convertible note payable due June 30, 2026 25,000 - 25,000 Total long-term convertible notes payable 25,000 - 25,000 Total notes and convertible notes payable $ 1,462,307 $ (26,155 ) $ 1,436,152 As of March 31, 2023 Face Value Discount Carrying Value 6% Convertible promissory notes payable $ 560,000 $ - $ 560,000 6% Convertible notes payable due January 18, 2022 325,000 - 325,000 6% Convertible note payable due July 1, 2022 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 (9,475 ) 187,525 6% Convertible note payable due December 31, 2023 250,000 (31,755 ) 218,245 0% Note Payable dated October 23, 2017 (as amended) 55,307 - 55,307 Total short-term notes and convertible notes payable $ 1,437,307 $ (41,230 ) $ 1,396,077

Note 1 - Background and Signi_2

Note 1 - Background and Significant Accounting Policies (Details Textual)	3 Months Ended
	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 USD ($) shares	Dec. 31, 2022
Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs	$ 2,374,261
Amortization of Intangible Assets	624	$ 20,086
Entertainment, License Agreement for Program Material, Capitalized Cost	0
Goodwill and Intangible Asset Impairment	$ 42,195
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares	162,611,301	123,013,087
Patents [Member] | UNITED STATES
Finite-Lived Intangible Assets, Number			6
Patents [Member] | UNITED STATES | GBS Global Biopharma, Inc [Member]
Finite-Lived Intangible Assets, Number			4
Patents [Member] | Non-US [Member]
Finite-Lived Intangible Assets, Number	3		8
Patents Pending [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 0
Patents Pending [Member] | UNITED STATES
Finite-Lived Intangible Assets, Number			18
Indefinite-Lived Intangible Assets, Pending, Number	10
Patents Pending [Member] | Non-US [Member]
Indefinite-Lived Intangible Assets, Pending, Number	35
Licensed Patents [Member] | UNITED STATES
Finite-Lived Intangible Assets, Number			2

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Mar. 31, 2023
Retained Earnings (Accumulated Deficit)	$ (108,978,436)		$ (108,705,315)
Working Capital (Deficit)	(4,655,504)		$ (4,450,202)
Net Cash Provided by (Used in) Operating Activities	$ (105,301)	$ (292,043)

Note 3 - Convertible Notes (Det

Note 3 - Convertible Notes (Details Textual)							1 Months Ended			3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Mar. 04, 2022 USD ($)	Jan. 20, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 14, 2021 USD ($)	Dec. 29, 2020 USD ($)	Oct. 23, 2017 USD ($)	Mar. 31, 2022 USD ($)	Jul. 31, 2017 USD ($) $ / shares	Mar. 31, 2017 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	May 31, 2017 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Dec. 18, 2020 USD ($) $ / shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Aug. 10, 2020 USD ($)	Jul. 24, 2020 USD ($)
Amortization of Debt Discount (Premium)										$ 15,075	$ 15,976
Debt Instrument, Face Amount										1,462,307
Proceeds from Convertible Debt										25,000	$ 0
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants									4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 0.60			$ 0.60
Warrants and Rights Outstanding, Term (Year)									3 years			3 years
Class of Warrant or Right, Issued (in shares) | shares												8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares												1
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]
Debt Instrument, Convertible, Number of Warrants								4,000
Class of Warrant or Right, Issued During Period (in shares) | shares																788,000
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 0.65					$ 0.60
Warrants and Rights Outstanding, Term (Year)													3 years
Class of Warrant or Right, Issued (in shares) | shares													28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares													1
Warrants Issued in September 30, 2023, Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 0.10
Warrants and Rights Outstanding, Term (Year)																3 years
Warrants and Rights Outstanding																$ 13,396
Promissory Note [Member]
Debt Instrument, Face Amount										1,437,307						1,437,307
GB Sciences Nopah, LLC [Member]
Financing Receivable, after Allowance for Credit Loss, Total			$ 3,025,000				$ 60,500							$ 3,025,000			$ 60,500
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount			74,647	$ 74,647
Teco Subsidiaries [Member] | The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total			1,025,000		$ 3,025,000									1,025,000
Increase (Decrease) in Notes Receivable, Current					975,000
Notes Receivable, Maximum Allowed Prepayments On Note					325,000
Disposal Group, Including Discontinued Operation, Consideration					$ 4,000,000
Gain (Loss) on Amendment to Line of Credit																		$ (650,000)
Notes Receivable, Additional Advances														50,000
Interest and Debt Expense, Total														12,510
Promissory Note [Member]
Debt Instrument, Face Amount										25,000
Convertible Debt [Member]
Debt Instrument, Unamortized Discount										4,859
Interest Expense, Debt										11,169
Interest Payable										206,939
Convertible Notes Payable, Total		$ 560,000
Debt Instrument, Debt Default, Amount										1,060,000
Repayments of Convertible Debt		$ 500,000
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License						$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]
Ownership of License						100%
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]
Ownership of License						100%
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member]
Debt, Current										1,436,152
Debt Instrument, Unamortized Discount							6,500			26,155					$ 81,250		6,500
Interest Expense, Debt										40,040
Amortization of Debt Discount (Premium)										15,075
Debt Instrument, Face Amount															425,000
Debt Instrument, Convertible, Beneficial Conversion Feature															347,000
Proceeds from Convertible Debt										25,000					$ 543,750		$ 50,000
The 0% Note Payable Dated October 23, 2017 [Member] | Convertible Notes Payable [Member]
Debt Instrument, Face Amount										55,307
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Debt Instrument, Unamortized Discount						$ 178,933
Debt Instrument, Interest Rate, Stated Percentage						0%													0%
Debt Instrument, Face Amount						$ 700,000
Debt Instrument, Term (Year)						3 years
Debt Instrument, Present Value						$ 521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)						20.30%
Notes Payable, Current, Total			$ 369,445											$ 369,445
Notes Payable, Principal and Interest	$ 201,532
Notes Payable, Principal and Interest, After Modified Terms	179,127
Repayment of Notes Payable	75,000
Debt Instrument, Monthly Payment, Amount	$ 5,000
Debt Instrument, Interest Rate, Stated Percentage, After Term Modification	8%
Gain (Loss) on Extinguishment of Debt, Total							$ 22,405
Notes Payable, Current and Noncurrent										55,307
Interest Payable										1,454
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member]
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition																			$ 190,272
The 0% Note Payable Dated October 23, 2017 [Member] | Convertible Debt [Member]
Debt Instrument, Face Amount																$ 55,307
The July 24 Note [Member] | Revolving Credit Facility [Member]
Debt Instrument, Interest Rate, Stated Percentage																				8%
Line of Credit Facility, Maximum Borrowing Capacity																				$ 500,000
The July 24 Note [Member] | Teco Subsidiaries [Member]
Financing Receivable, after Allowance for Credit Loss, Total																				$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding																				3
March 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member]
Debt Instrument, Unamortized Discount												$ 1,933,693
Debt Instrument, Interest Rate, Stated Percentage									6%
Debt Instrument, Face Amount												$ 2,000,000
Debt Instrument, Term (Year)												3 years
Debt Instrument, Face Amount Per Note									$ 1,000
Debt Instrument, Convertible, Beneficial Conversion Feature												$ 904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants												$ 1,029,003
March 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments									4,000			8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares									$ 0.25
July 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member]
Debt Instrument, Unamortized Discount													$ 7,092,796
Debt Instrument, Face Amount													$ 7,201,000
Debt Instrument, Term (Year)								3 years					3 years
Debt Instrument, Face Amount Per Note								$ 1,000
Debt Instrument, Convertible, Beneficial Conversion Feature													$ 3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants													$ 3,950,191
July 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments								4,000					28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares								$ 0.25
July 2017 Convertible Note Offering [Member] | Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage								6%
March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Unamortized Discount										21,296
Interest Expense, Debt										21,307
Amortization of Debt Discount (Premium)										10,458
Interest Payable										93,222
March And July 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																$ 0.10
Debt Instrument, Extended Amount																$ 197,000
Convertible Notes Payable, Total																1,257,000
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount																46,886
Interest Expense, Debt										7,564
Amortization of Debt Discount (Premium)										4,617
Interest Payable										70,919
Debt Instrument, Convertible, Beneficial Conversion Feature																$ 33,490
The 6 % Convertible Note Payable Dated December 31, 2023 [Member]
Debt Instrument, Interest Rate, Stated Percentage															6%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares															$ 0.05
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount															$ 625,000
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Convertible Notes Payable [Member]
Debt Instrument, Face Amount										$ 250,000
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member]
Debt Instrument, Face Amount															375,000
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount															$ 250,000

Note 3 - Notes Payable and Line

Note 3 - Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details) - USD ($)	Jun. 30, 2023	Mar. 31, 2023	Oct. 23, 2017
Short-Term Notes Payable	$ 1,462,307
Discount, short-term notes payable	(26,155)
Discount, long-term notes payable	26,155
Total notes and convertible notes payable	1,436,152
Discount, short-term notes payable	(26,155)	$ (41,230)
Promissory Note [Member]
Short-Term Notes Payable	25,000
Discount, short-term notes payable	0
Carrying value, long-term notes payable	25,000
Discount, long-term notes payable	0
The 6 % Note Payable Dated December 31, 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable		50,000
Carrying value, short-term notes payable		50,000
Discount, short-term notes payable		0
Discount, long-term notes payable		0
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable		197,000
Discount, short-term notes payable		(9,475)
Carrying value, long-term notes payable		187,525
Discount, long-term notes payable		9,475
The 6% Convertible Note Payable Due December 31, 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable		250,000
Discount, short-term notes payable		(31,755)
Carrying value, long-term notes payable		218,245
Discount, long-term notes payable		31,755
The 0% Note Payable Dated October 23, 2017 [Member] | Convertible Debt [Member]
Short-Term Notes Payable		55,307
Discount, short-term notes payable		0
Carrying value, long-term notes payable		55,307
Discount, long-term notes payable		0
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Short-Term Notes Payable			$ 700,000
The 6 Percent Note Payable Dated June 30, 2026 [Member] | Convertible Debt [Member]
Short-Term Notes Payable	25,000
Discount, short-term notes payable	0
Carrying value, long-term notes payable	25,000
Discount, long-term notes payable	0
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Short-Term Notes Payable	560,000	560,000
Carrying value, short-term notes payable	560,000	560,000
Discount, short-term notes payable		0
Convertible Notes Payable [Member] | The 6% Notes Payable Due January 18, 2022 [Member]
Short-Term Notes Payable	325,000	325,000
Carrying value, short-term notes payable	325,000	325,000
Discount, short-term notes payable		0
Convertible Notes Payable [Member] | The 6% Notes Payable Due July 1, 2022 [Member]
Short-Term Notes Payable	50,000
Carrying value, short-term notes payable	50,000
Discount, short-term notes payable	0
Discount, long-term notes payable	0
Convertible Notes Payable [Member] | The 6 % Note Payable Dated September 30, 2023 [Member]
Short-Term Notes Payable	197,000
Discount, short-term notes payable	(4,859)
Carrying value, long-term notes payable	192,141
Discount, long-term notes payable	4,859
Convertible Notes Payable [Member] | The 6 % Convertible Note Payable Dated December 31, 2023 [Member]
Short-Term Notes Payable	250,000
Discount, short-term notes payable	(21,296)
Carrying value, long-term notes payable	228,704
Discount, long-term notes payable	21,296
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Short-Term Notes Payable	55,307
Discount, short-term notes payable	0
Carrying value, long-term notes payable	55,307
Discount, long-term notes payable	0
Promissory Note [Member]
Short-Term Notes Payable	1,437,307	1,437,307
Carrying value, short-term notes payable		1,396,077
Discount, short-term notes payable	(26,155)
Carrying value, long-term notes payable	1,411,152
Discount, long-term notes payable	$ 26,155
Discount, short-term notes payable		$ (41,230)

Note 4 - Capital Transactions (

Note 4 - Capital Transactions (Details Textual) - USD ($)			3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 09, 2022	May 09, 2022	Jun. 30, 2023	Dec. 31, 2022	Mar. 31, 2023	Aug. 25, 2022	Jun. 30, 2022
Class of Warrant or Right, Expired During Period (in shares)			3,490,834
Class of Warrant or Right, ExpiredDuring Period, Exercise Price (in dollars per share)			$ 0.10
Proceeds from Issuance of Private Placement					$ 221,650
Warrants Issued to Investors in Private Placements [Member]
Number of Warrant Received, Per Unit (in shares)		1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.10		$ 0.10
Warrants and Rights Outstanding, Term (Year)				5 years			5 years
Stock Issued During Period, Shares, New Issues (in shares)				56,835,004
Class of Warrant or Right, Issued During Period (in shares)				56,835,004
Compensation Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.03
Warrants and Rights Outstanding, Term (Year)				5 years
Class of Warrant or Right, Issued During Period (in shares)				5,416,834
Class of Warrant or Right, Fair Value Assumption, Exercise Price (in dollars per share)				$ 0.0273
Warrants and Rights Outstanding				$ 147,879
Private Placement [Member]
Sale of Units, Maximum Units Allowed in Private Placement	$ 2,000,000	$ 565,000
Sale of Units, Price Per Unit (in dollars per share)		$ 0.03
Number of Common Stock Received, Per Unit (in shares)		1
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)			1,150,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price (in dollars per share)			$ 0.05
Share-Based Payment Arrangement, Option [Member] | Seven Persons [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Authorized, Percentage of Common Shares Issued and Outstanding						13%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percentage of Value Per Share						80%

Note 6 - Related Party Transa_2

Note 6 - Related Party Transactions (Details Textual)	Jun. 30, 2023 USD ($)
Chief Executive Officer [Member]
Accounts Payable, Current	$ 108,816
President and Director [Member]
Accounts Payable, Current	$ 12,095

Note 7 - Sale of Membership I_2

Note 7 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual)						3 Months Ended		12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 14, 2021 USD ($)	Aug. 10, 2020 USD ($)	Mar. 24, 2020 USD ($)	Nov. 27, 2019	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Oct. 23, 2017
Other Nonoperating Income (Expense)						$ 75,000	$ 0
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage			0%							0%
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership					100%
Noncash or Part Noncash Divestiture, Amount of Consideration Received			$ 312,315
Nevada Subsidiaries [Member]
Sale of Stock, Percentage of Ownership				100%
Teco Subsidiaries [Member]
Sale of Stock, Consideration Received on Transaction				$ 8,000,000
Notes Receivable, Interest Rate				8%
GB Sciences Nopah, LLC [Member]
Notes Reduction			$ 237,668
Sale of Stock, Percentage of Ownership before Transaction	100%
Sale of Stock, Percentage of Ownership after Transaction	0%
Financing Receivable, after Allowance for Credit Loss, Total	$ 3,025,000							$ 60,500	$ 60,500
Quarterly Interest Only Payments on Note Receivable, Years								1	1
Number of Quarterly Principal and Interest Payments on Note Receivable								7	7
Note Receivable, Quarterly Principal and Interest Installment								$ 201,774
Final Payment, Principal and Interest Payments Due on Note Receivable								2,014,225	$ 2,014,225
Note Receivable, Interest Only, Monthly									$ 60,500
Asset Impairment Charges, Total								$ 3,025,000
Other Nonoperating Income (Expense)						$ 75,000
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount	$ 74,647	$ 74,647

Note 8 - Subsequent Events (Det

Note 8 - Subsequent Events (Details Textual) - USD ($)		3 Months Ended
	Jul. 01, 2023	Jun. 30, 2023	Jun. 30, 2022
Proceeds from Convertible Debt		$ 25,000	$ 0
Subsequent Event [Member]
Proceeds from Warrant Exercises	$ 80,025
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	8,002,500
Subsequent Event [Member] | Three Convertible Notes Payable [Member]
Proceeds from Convertible Debt	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	6%
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.03